Vanguard Capital Management
ACAD icon

Vanguard Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Vanguard Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$146M Buy
5,763,750
+102,350
+2% +$2.25M ﹤0.01% 1335
2026
Q1 		$126M Buy
+5,661,400
New +$135M ﹤0.01% 1344

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Vanguard Capital Management's ACAD Position: Q2 2026 in Review

Vanguard Capital Management increased its Acadia Pharmaceuticals (ACAD) stake by 1.8% in Q2 2026, buying an estimated $2.25M and bringing the position to 5,763,750 shares worth $146M. The position accounts for ﹤0.01% of the portfolio, ranked #1335.

Vanguard Capital Management first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 349 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Vanguard Capital Management held 5,763,750 shares of Acadia Pharmaceuticals worth $146M as of Q2 2026.
  • Vanguard Capital Management bought 102,350 Acadia Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • Acadia Pharmaceuticals made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #1335 holding.
  • Vanguard Capital Management first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 349 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.